-
1Academic Journal
-
2Academic Journal
Συγγραφείς: O. N. Titova, V. A. Volchkov, N. A. Kuzubova, D. B. Sklyarova, О. Н. Титова, В. А. Волчков, Н. А. Кузубова, Д. Б. Склярова
Πηγή: Meditsinskiy sovet = Medical Council; № 23 (2023); 128-132 ; Медицинский Совет; № 23 (2023); 128-132 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: иммуноглобулин Е, genetically engineered biological therapy, benralizumab, dupilumab, personalized medicine, eosinophilic inflammation, immunoglobulin E, генно-инженерная биологическая терапия, бенрализумаб, дупилумаб, персонализированная медицина, эозинофильное воспаление
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8011/7102; Asher MI, García-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56(6):2002094. https://doi.org/10.1183/13993003.02094-2020.; Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. https://doi.org/10.1183/09031936.00202013.; Trevor J, Lugogo N, Carr W, Moore C, Soong W, Panettieri Jr RA et al. Severe asthma exacerbations in the United States: Incidence, characteristics, predictors, and effects of biologic treatments. Ann Allergy Asthma Immunology. 2021;127(5):579–587. https://doi.org/10.1016/j.anai.2021.07.010.; Pavord ID. Eosinophilic phenotypes of airway disease. Ann Am Thorac Soc. 2013;(10):143–149. https://doi.org/10.1513/Annal-sATS.201306-168AW.; Kaur R, Chupp GJ. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1–12. https://doi.org/10.1016/j.jaci.2019.05.031.; Ramírez-Jiménez F, Pavón-Romero GF, Velásquez-Rodríguez JM, López-Garza MI, Lazarini-Ruiz JF, Gutiérrez-Quiroz KV, Teran LM. Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future. Pharmaceuticals (Basel). 2023;16(2):270. https://doi.org/10.3390/ph16020270.; Kavanagh JE, Hearn AP, Jackson DJ. A pragmatic guide to choosing biologic therapies in severe asthma. Breathe (Sheff). 2021;17(4):210144. https://doi.org/10.1183/20734735.0144-2021.; Kavanagh JE, Hearn AP, Dhariwal J, d’Ancona G, Douiri A, Roxas C et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. https://doi.org/10.1016/j.chest.2020.08.2083.; Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. https://doi.org/10.1016/S0140-6736(16)31324-1.; FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. https://doi.org/10.1016/S01406736(16)31322-8.; Pham DN. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report. J Med Case Rep. 2021;15(1):103. https://doi.org/10.1186/s13256-021-02663-2.; Guttman-Yassky E, Bahadori L, Brooks L, Ckark L, Grindebacke H, Ho CN et al. Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial. J Eur Acad Dermatol Venereol. 2023;37(10):e1211–e1214. https://doi.org/10.1111/jdv.19195.; Alenazi SD. Atopic dermatitis: a brief review of recent advances in its management. Dermatol Reports. 2023;15(3):9678. https://doi.org/10.4081/dr.2023.9678.; Salter B, Lacy P, Mukherjee M. Biologics in Asthma: A Molecular Perspective to Precision Medicine. Front Pharmacol. 2022;(12):793409. https://doi.org/10.3389/fphar.2021.793409.; Sardon-Prado O, Diaz-Garcia C, Corcuera-Elosegui P, Korta-Murua J, Valverde-Molina J, Sanchez-Solis M. Severe Asthma and Biological Therapies: Now and the Future. J Clin Med. 2023;12(18):5846. https://doi.org/10.3390/jcm12185846.; Rogers L, Jesenak M, Bjermer L, Hanania NA, Seys SF, Diamant Z. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023;218:107414. https://doi.org/10.1016/j.rmed.2023.107414.; López-Viña A, Díaz Campos RM, Trisan Alonso A, Melero Moreno C. Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach. Front Allergy. 2022;(3):1007593. https://doi.org/10.3389/falgy.2022.1007593.
-
3Academic Journal
Συγγραφείς: Nesterovska, O. A., Stupnytska, G. Y., Fediv, O. I.
Πηγή: Буковинський медичний вісник; Том 24, № 3 (95) (2020); 60-67
Буковинский медицинский вестник; Том 24, № 3 (95) (2020); 60-67
Bukovinian Medical Herald; Том 24, № 3 (95) (2020); 60-67Θεματικοί όροι: chronic obstructive pulmonary disease, bronchial asthma, eosinophilic inflammation, smoking, бронхиальная астма, хроническое обструктивное заболевание легких, эозинофильное воспаление, курение, 3. Good health, хронічне обструктивне захворювання легень, бронхіальна астма, еозинофільне запалення, куріння
Περιγραφή αρχείου: application/pdf
-
4Academic Journal
Συγγραφείς: A. Yu. Kraposhina, E. A. Sobko, I. V. Demko, A. B. Katser, O. V. Kazmerchuk, Yu. I. Abramov, S. V. Chubarova, А. Ю. Крапошина, Е. А. Собко, И. В. Демко, А. Б. Кацер, О. В. Казмерчук, Ю. И. Абрамов, С. В. Чубарова
Πηγή: Meditsinskiy sovet = Medical Council; № 18 (2022); 20-28 ; Медицинский Совет; № 18 (2022); 20-28 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: эозинофильное воспаление, asthma pathogenesis, targeted therapy, genetically engineered biological therapy, T2 endotype markers, eosinophilic inflammation, патогенез астмы, таргетная терапия, генно-инженерная биологическая терапия, маркеры Т2-эндотипа
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/7116/6388; Corren J. Asthma phenotypes and endotypes: an evolving paradigm for classification. Discov Med. 2013;15(83):243–249. Available at: https://www.discoverymedicine.com/Jonathan-Corren/2013/04/26/asthmaphenotypes-and-endotypes-an-evolving-paradigm-for-classification/.; Thomas M., Gruffydd-Jones K., Stonham C., Ward S., Macfarlane T.V. Assessing asthma control in routine clinical practice: use of the Royal College of Physicians ‘3 questions’. Prim Care Respir J. 2009;18(2):83–88. https://doi.org/10.3132/pcrj.2008.00045.; Геппе Н.А., Колосова Н.Г., Кондюрина Е.Г., Малахов А.Б., Мизерницкий Ю.Л., Ревякина В.А. (ред.). Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 5-е изд. М.: Оригиналмакет; 2017. 160 с. Режим доступа: http://astgmu.ru/wp-content/uploads/2018/10/Natsionalnaya-programma-BA-u-detej.-Strategiyalecheniya-i-profilaktika.pdf.; Masoli M., Fabian D., Holt S., Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy. 2004;59(5):469–478. https://doi.org/10.1111/j.1398-9995.2004.00526.x.; Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373(9678):1905–1917. https://doi.org/10.1016/S0140-6736(09)60326-3.; Pepper A.N., Renz H., Casale T.B., Garn H. Biologic Therapy and Novel Molecular Targets of Severe Asthma. J Allergy Clin Immunol Pract. 2017;5(4):909–916. https://doi.org/10.1016/j.jaip.2017.04.038.; Lötvall J., Akdis C.A., Bacharier L.B., Bjermer L., Casale T.B., Custovic A. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–360. https://doi.org/10.1016/j.jaci.2010.11.037.; Carr T.F., Zeki A.A., Kraft M. Eosinophilic and Noneosinophilic Asthma. Am J Respir Crit Care Med. 2018;197(1):22–37. https://doi.org/10.1164/rccm.201611-2232PP.; Leckie M.J., ten Brinke A., Khan J., Diamant Z., O’Connor B.J., Walls C.M. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148. https://doi.org/10.1016/s0140-6736(00)03496-6.; Kips J.C., O’Connor B.J., Langley S.J. Woodcock A., Kerstjens H.A.M., Postma D.S. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med. 2003;167(12):1655–1659. https://doi.org/10.1164/rccm.200206-525OC.; Svenningsen S., Nair P. Asthma Endotypes and an overview of targeted therapy for asthma. Front Med (Lausanne). 2017;4:158. https://doi.org/10.3389/fmed.2017.00158.; Moore W.C., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X. et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. https://doi.org/10.1164/rccm.200906-0896OC.; Loza M.J., Djukanovic R., Chung K.F., Horowitz D., Ma K., Branigan P. et al. Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respir Res. 2016;17(1):165. https://doi.org/10.1186/s12931-016-0482-9.; Lefaudeux D., De Meulder B., Loza M.J., Peffer N., Rowe A., Baribaud F. et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2016;139(6):1797–1807. https://doi.org/10.1016/j.jaci.2016.08.048.; Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. https://doi.org/10.1056/NEJMoa0808991.; Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012;42(5):650–658. https://doi.org/10.1111/j.1365-2222.2011.03929.x.; Nair P. Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med. 2014;371(13):1249–1251. https://doi.org/10.1056/NEJMe1408614.; Xu X., Reitsma S., Wang D.Y., Fokkens W.J. Highlights in the advances of chronic rhinosinusitis. Allergy. 2021;76(11):3349–3358. https://doi.org/10.1111/all.14892.; Asano K., Ueki S., Tamari M., Imoto Y., Fujieda S., Taniguchi M. Adult‐onset eosinophilic airway diseases. Allergy. 2020;75(12):3087–3099. https://doi.org/10.1111/all.14620.; Vinall S.L., Townsend E.R., Pettipher R. A paracrine role for chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) in mediating chemotactic activation of CRTH2+ CD4+ T helper type 2 lymphocytes. Immunology. 2007;121(4):577–584. https://doi.org/10.1111/j.1365-2567.2007.02606.x.; Barnes P.J. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546–3556. https://doi.org/10.1172/JCI36130.; Robinson D., Humbert M., Buhl R., Cruz A.A., Inoue H., Korom S. et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161–175. https://doi.org/10.1111/cea.12880.; Cosmi L., Liotta F., Maggi L., Annunziato F. Role of type 2innate lymphoid cells in allergic diseases. Curr Allergy Asthma Rep. 2017;17(10):66. https://doi.org/10.1007/s11882-017-0735-9.; Hammad H., de Heer H.J., Soullie T., Hoogsteden H.C., Trottein F., Lambrecht B.N. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol. 2003;171(8):3936–3940. https://doi.org/10.4049/jimmunol.171.8.3936.; Faveeuw C., Gosset P., Bureau F., Angeli V., Hirai H., Maruyama T. et al. Prostaglandin D2 inhibits the production of interleukin-12 in murine dendritic cells through multiple signaling pathways. Eur J Immunol. 2003;33(4):889–898. https://doi.org/10.1002/eji.200323330.; Gosset P., Pichavant M., Faveeuw C., Bureau F., Tonnel A.B., Trottein F. Prostaglandin D2 affects the differentiation and functions of human dendritic cells: impact on the T cell response. Eur J Immunol. 2005;35(5):1491–1500. https://doi.org/10.1002/eji.200425319.; Tanaka K., Hirai H., Takano S., Nakamura M., Nagata K. Effects of prostaglandin D2 on helper T cell functions. Biochem Biophys Res Commun. 2004;316(4):1009–1014. https://doi.org/10.1016/j.bbrc.2004.02.151.; Wills-Karp M., Finkelman F.D. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal. 2008;1(51):pe55. https://doi.org/10.1126/scisignal.1.51.pe55.; Bartemes K.R., Kephart G.M., Fox S.J., Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol. 2014;134(3):671–678.e4. https://doi.org/10.1016/j.jaci.2014.06.024.; Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071. https://doi.org/10.1164/rccm.200701-085OC.; Hirose K., Iwata A., Tamachi T., Nakajima H. Allergic airway inflammation: key players beyond the Th2 cell pathway. Immunol Rev. 2017;278(1):145– 161. https://doi.org/10.1111/imr.12540.; Khorasanizadeh M., Eskian M., Assa’ad A.H., Camargo C.A., Jr,, Rezaei N. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma. Int Rev Immunol. 2016;35(4):294–311. https://doi.org/10.3109/08830185.2015.1128901.; Nair P., Pizzichini M.M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–993. https://doi.org/10.1056/NEJMoa0805435.; Samitas K., Zervas E., Gaga M. T2-low asthma: currentapproach to diagnosis and therapy. Curr Opin Pulm Med. 2017;23(1):48–55. https://doi.org/10.1097/MCP.0000000000000342.; Licari A., Castagnoli R., Brambilla I., Marseglia A., Tosca M.A., Marseglia G.L. et al. New approaches for identifyingand testing potential new anti-asthma agents. Expert Opin Drug Discov. 2018;13(1):51–63. https://doi.org/10.1080/17460441.2018.1396315.; Saglani S., Lloyd C.M. Eosinophils in the pathogenesis of paediatric severe asthma. Curr Opin Allergy Clin Immunol. 2014;14(2):143–148. https://doi.org/10.1097/ACI.0000000000000045.; Schleich F.N., Manise M., Sele J., Henket M., Seidel L., Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013;13:11. https://doi.org/10.1186/1471-2466-13-11.; Cowan D.C., Taylor D.R., Peterson L.E., Cowan J.O., Palmay R., Williamson A. et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol. 2015;135(4):877–883.e1. https://doi.org/10.1016/j.jaci.2014.10.026.; Price D., Wilson A.M., Chisholm A., Rigazio A., Burden A., Thomas M. et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1–12. https://doi.org/10.2147/JAA.S97973.; Busse W., Spector S., Rosen K., Wang Y., Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485–486.e11. https://doi.org/10.1016/j.jaci.2013.02.032.; Wagener A.H., de Nijs S.B., Lutter R., Sousa A.R., Weersink E.J., Bel E.H. et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115– 120. https://doi.org/10.1136/thoraxjnl-2014-205634.; Ullmann N., Bossley C.J., Fleming L., Silvestri M., Bush A., Saglani S. Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma. Allergy. 2013;68(3):402–406. https://doi.org/10.1111/all.12101.; Bjerregaard A., Laing I.A., Backer V., Sverrild A., Khoo S.K., Chidlow G. et al. High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus-induced exacerbations: a prospective cohort study. Clin Exp Allergy. 2017;47(8):1007–1013. https://doi.org/10.1111/cea.12935.; Baraldi E., de Jongste J.C. European Respiratory Society/American Thoracic Society (ERS/ATS). Task Force. Measurement of exhaled nitric oxide in children, 2001. Eur Respir J. 2002;20(1):223–237. https://doi.org/10.1183/09031936.02.00293102.; Dweik R.A., Boggs P.B., Erzurum S.C., Irvin C.G., Leigh M.W., Lundberg J.O. et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. https://doi.org/10.1164/rccm.9120-11ST.; Pijnenburg M.W., De Jongste J.C. Exhaled nitric oxide in childhood asthma: a review. Clin Exp Allergy. 2008;38(2):246–259. https://doi.org/10.1111/j.1365-2222.2007.02897.x.; Giannetti M.P., Cardet J.C. Interleukin-5 antagonists usher in a new generation of asthma therapy. Curr Allergy Asthma Rep. 2016;16(11):80. https://doi.org/10.1007/s11882-016-0662-1.; Nannini L.J. Treat to target approach for asthma. J Asthma. 2020;57(6):687– 690. https://doi.org/10.1080/02770903.2019.1591443.; Normansell R., Walker S., Milan S.J., Walters E.H., Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. https://doi.org/10.1002/14651858.CD003559.pub4.; Farne H.A., Wilson A., Powell C., Bax L., Milan S.J. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;(9):CD010834. https://doi.org/10.1002/14651858.CD010834.pub3.; Zayed Y., Kheiri B., Banifadel M., Hicks M., Aburahma A., Hamid K. et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2019;56(10):1110–1119. https://doi.org/10.1080/02770903.2018.1520865.; Fajt M.L., Wenzel S.E. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2):299–310. https://doi.org/10.1016/j.jaci.2014.12.1871.; Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. https://doi.org/10.1164/rccm.200208-789OC.; Pavord I., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. https://doi.org/10.1016/S0140-6736(12)60988-X.; Hoshino M., Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012;83(6):520–528. https://doi.org/10.1159/000334701.; Tajiri T., Niimi A., Matsumoto H., Ito I., Oguma T., Otsuka K. et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol. 2014;113(4):470–475. https://doi.org/10.1016/j.anai.2014.06.004.; Tajiri T., Matsumoto H., Hiraumi H., Ikeda H., Morita K., Izuhara K. et al. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol. 2013;110(5):387–388. https://doi.org/10.1016/j.anai.2013.01.024.; Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F. et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466. https://doi.org/10.1056/NEJMoa1304048.; Wechsler M.E. Inhibiting IL-4 and IL-13 in difficult-to-control asthma. N Engl J Med. 2013;368(26):2511–2513. https://doi.org/10.1056/NEJMe1305426.; Garlisi C.G., Kung T.T., Wang P., Minnicozzi M., Umland S.P., Chapman R.W. et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol. 1999;20(2):248–255. https://doi.org/10.1165/ajrcmb.20.2.3327.; Ortega H.G., Liu M.C., Pavord I.D., Brusselle G.G., FitzGerald J.M., Chetta A. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. https://doi.org/10.1056/NEJMoa1403290.; Castro M., Mathur S., Hargreave F. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132. https://doi.org/10.1164/rccm.201103-0396OC.; Castro M., Zangrilli J., Wechsler M.E., Bateman E.D., Brusselle G.G., Bardin P. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. https://doi.org/10.1016/S2213-2600(15)00042-9.; Mukherjee M., Paramo F.A., Kjarsgaard M., Salter B., Nair G., LaVigne N. et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38–46. https://doi.org/10.1164/rccm.201707-1323OC.; Walsh G.M. Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Curr Opin Investig Drugs. 2010;11(11):1305–1312. Available at: https://pubmed.ncbi.nlm.nih.gov/21157650/.; May R.D., Monk P.D., Cohen E.S., Manuel D., Dempsey F., Davis N.H.E. et al. Preclinical development of CAT-354, an IL-13-neutralising antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol. 2012;166(1):177–193. https://doi.org/10.1111/j.1476-5381.2011.01659.x.; Piper E., Brightling C., Niven R., Oh C., Faggioni R., Poon K. et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–338. https://doi.org/10.1183/09031936.00223411.; Noonan M., Korenblat P., Mosesova S., Scheerens H. , Arron J.R., Zheng Y. et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol. 2013;132(3):567–574. https://doi.org/10.1016/j.jaci.2013.03.051.; Diamant Z., Gauvreau G.M., Cockcroft D.W., Boulet L.P., Sterk P.J., de Jongh F.H.C. et al. Inhaled allergen bronchoprovocation tests. J Allergy Clin Immunol. 2013;132(5):1045–1055.e6. https://doi.org/10.1016/j.jaci.2013.08.023.; Scheerens H., Arron J.R., Zheng Y., Erickson R.W., Choy D.F., Harris J.M. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014;44(1):38–46. https://doi.org/10.1111/cea.12220.; Jiang H., Harris M.B., Rothman P. IL-4/IL-13 signalling beyond JAK/STAT. J Allergy Clin Immunol. 2000;105(6 Pt 1):1063–1070. https://doi.org/10.1067/mai.2000.107604.; Liu Y., Zhang S., Li D.W., Jiang S.J. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS ONE. 2013;8(3):e59872. https://doi.org/10.1371/journal.pone.0059872.; Parker J.M., Oh C.K., LaForce C., Miller S.D., Pearlman D.S., Le C. et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011;11:14. https://doi.org/10.1186/1471-2466-11-14.; Cheng G., Arima M., Honda K., Hirata H., Eda F., Yoshida N. et al. Antiinterleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med. 2002;166(3):409–416. https://doi.org/10.1164/rccm.2105079.; Yang G., Li L., Volk A., Emmell E., Petley T., Giles-Komar J. et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J Pharmacol Exp Ther. 2005;313(1):8–15. https://doi.org/10.1124/jpet.104.076133.; Singh D., Kane B., Molfino N.A., Faggioni R., Roskos L., Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med. 2010;10:3. https://doi.org/10.1186/1471-2466-10-3.; Corren J., Lemanske R.F., Hanania N.A., Korenblat P.E., Parsey M.V., Arron J.R. et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098. https://doi.org/10.1056/NEJMoa1106469.; Laviolette M., Gossage D., Gauvreau G., Leigh R., Olivenstein R., Katial R. et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096. https://doi.org/10.1016/j.jaci.2013.05.020.; Pérez de Llano L.A., Cosío B.G., Domingo C., Urrutia I., Bobolea I., Valero A. et al. Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: A multicenter, open-label pilot study. J Allergy Clin Immunol Pract. 2019;7(7):2277–2283.e2. https://doi.org/10.1016/j.jaip.2019.01.017.; Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. https://doi.org/10.1016/S0140-6736(16)31324-1.; FitzGerald J.M., Bleecker E., Nair P., Korn S., Ohta K., Lommatzsch M. et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. https://doi.org/10.1016/S0140-6736(16)31322-8.; Parulekar A.D., Diamant Z., Hanania N.A. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far? Curr Opin Pulm Med. 2017;23(1):3–11. https://doi.org/10.1097/MCP.0000000000000343.; Menzies-Gow A., Ponnarambil S., Downie J., Bowen K., Hellqvist Å., Colice G. DESTINATION: a phase 3, multicentre, randomized, doubleblind, placebo-controlled, parallel-group trial to evaluate the longterm safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):279. https://doi.org/10.1186/s12931-020-01541-7.; Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. https://doi.org/10.1183/09031936.00202013.
-
5Academic Journal
Συγγραφείς: Natalia V. Shakhova, Н. В. Шахова
Συνεισφορές: Not specified, Не указан
Πηγή: Current Pediatrics; Том 18, № 5 (2019); 339-345 ; Вопросы современной педиатрии; Том 18, № 5 (2019); 339-345 ; 1682-5535 ; 1682-5527
Θεματικοί όροι: функция внешнего дыхания, bronchial asthma, periostin, eosinophilic inflammation, airway remodeling, pulmonary function test, бронхиальная астма, периостин, эозинофильное воспаление, ремоделирование дыхательных путей
Περιγραφή αρχείου: application/pdf
Relation: https://vsp.spr-journal.ru/jour/article/view/2231/893; Akids CA, Agache I. Global athlas of asthma. Zurich, European Academy of Allergy and Clinical Immunology; 2013. рр. 7-9.; Cezmi AI, Chivato AT, Hellings P et al. (ed.). EAACI WHITE PAPER on Research, Innovation and Quality Care. European Academy of Allergy and Clinical Immunology; 2018.; Global strategy for asthma management and prevention [updata 2019]. Global Initiative for Asthma; 2019. Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf.; James A, Hedlin G. Biomarkers for the phenotyping and monitoring of asthma in children. Сигг Тгeat Options Allergy. 2016;3(4): 439-452. doi:10.1007/s40521-016-0106-0.; Nuzzo PV, Buzzatti G, Ricci F, et al. Periostin: a novel prognostic and therapeutic target for genitourinary cancer? Clin Genitourin Сапсег. 2014;12(5):301-311. doi:10.1016/j.clgc.2014.02.005.; Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. JAllergy Clin Immunol. 2006;118(1):98-104. doi:10.1016/j.jaci.2006.02.046.; Соботюк Н.В, Гапоненко В.П., Бочанцев С.В., и др. Потенциальная роль сывороточного периостина в ранней диагностике бронхиальной астмы у детей // Вопросы современной педиатрии. — 2016. — Т. 15. — № 5. — С. 452-456. doi:10.15690/vsp.v15i5.1619.; Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993;294(1): 271-278. doi:10.1042/bj2940271.; Hoersch S, Andrade-Navarro MA. Periostin shows increased evolutionary plasticity in its alternatively spliced region. BMC Evo Biol. 2010;28:10-30. doi:10.1186/1471-2148-10-30.; Kudo А. Introductory review: periostin — gene and protein structure. Cell Mol Life Sci. 2017;74(23):4259-4268. doi:10.1007/s00018-017-2643-5.; Huber O, Sumper M. Algal-CAMs: isoforms of a cell adhesion molecule in embryos of the alga Volvox with homology to Drosophila fasciclin I. EMBO J. 1994;13(18):4212-4222. doi:10.1002/j.1460-2075.1994.tb06741.x.; Ulstrup JC, Jeansson S, Wiker HG, Harboe M. Relationship of secretion pattern and MPB70 homology with osteoblast-specific factor 2 to osteitis following Mycobacterium bovis BCG vaccination. Infect Immun. 1995;63(2):672-675.; Doliana R, Bot S, Bonaldo P, Colombatti A. EMI, a novel cysteine-rich domain of EMILINs and other extracellular proteins, interacts with the gC1q domains and participates in multimeriza-tion. FEBS Lett. 2000;484(2):164-168. doi:10.1016/s0014-5793(00)02140-2.; Kii I, Nishiyama T, Kudo A. Periostin promotes secretion of fibronectin from the endoplasmic reticulum. Biochem Biophy Res Commun. 2016;470(4):888-893. doi:10.1016/j.bbrc.2016.01.139.; Van Vliet AI, van Alderwegen IE, Baelde HJ, et al. Fibronectin accumulation in glomerulosclerotic lesions: self-assembly sites and the heparin II binding domain. Kidney Int. 2002;61(2):481-489. doi:10.1046/j.1523-1755.2002.00159.x.; Conway SJ, Izuhara K, Kudo Y et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014;71(7):1279-1288. doi:10.1007/s00018-013-1494-y.; Rosselli-Murai LK, Almeida LO, Zagni C, et al. Periostin responds to mechanical stress and tension by activating the MTOR signaling pathway. PLoS One. 2013;8(12):e83580. doi:10.1371/journal.pone.0083580.; Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor p. J Bone Miner Res. 1999;14(7): 1239-1249. doi:10.1359/jbmr.1999.14.7.1239.; Yuyama N, Davies DE, Akaiwa M, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine. 2002;19(6):287-296. doi:10.1006/cyto.2002.1972.; Izuhara K, Arima K, Yasunaga S. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. Curr Drug Targets Inflamm Allergy. 2002;1(3):263-269. doi:10.2174/1568010023344661.; Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007;104(40):15858-15863. doi:10.1073/pnas.0707413104.; Uysal P Birtekocak F, Karul AB. The relationship between serum TARC, TSLP and POSTN levels and childhood atopic dermatitis. Clin Lab. 2017;63(7):1071-1077. doi:10.7754/Clin.Lab.2017.161107.; Fujishima H, Okada N, Matsumoto K, et al. The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases. J Allergy Clin Immunol. 2016;138(2): 459-467:e2. doi:10.1016/j.jaci.2015.11.039.; Politi E, Angelakopoulou A, Grapsa D, et al. Filaggrin and perios-tin expression is altered in eosinophilic esophagitis and normalized with treatment. J Pediatr Gastroenterol Nutr. 2017;65(1):47-52. doi:10.1097/MPG.0000000000001419.; Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A. 2010;107(32):14170-14175. doi:10.1073/pnas.1009426107.; Shoda T, Futamura K, Kobayashi F, et al. Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells. Allergy. 2013;68(11):1467-1470. doi:10.1111all.12240.; Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118(1):98-104. doi:10.1016/j.jaci.2006.02.046.; Masuoka M, Shiraishi H, Ohta S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122(7):2590-2600. doi:10.1172/JCI58978.; Makita K, Mikami Y, Matsuzaki H, et al. Mechanism of periostin production in human bronchial smooth muscle cells. Int Arch Allergy Immunol. 2018;175(1-2):26-35. doi:10.1159/000485892.; Inoue Y, Izuhara K, Ohta S, et al. No increase in the serum periostin level is detected in elementary school-age children with allergic diseases. Allergol Int. 2015;64(3):289-290. doi:10.1016/j.alit.2015.04.001.; Fujitani H, Kasuga S, Ishihara T, et al. Age-related changes in serum periostin level in allergic and non-allergic children. Allergol Int. 2019;68(2):285-286. doi:10.1016/j.alit.2018.12.006.; Voehringer D, Reese TA, Huang X, et al. Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. J Exp Med. 2006;203: 1435-1446. doi:10.1084/jem.20052448.; Fahy JV. Type 2 inflammation in asthma — present in most, absent in many. Nat Rev Immunol. 2015;15(1):57-65. doi:10.1038/nri3786.; Agache IO. From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol. 2013;13:249-256. doi:10.1097/ACI.0b013e32836093dd.; Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875-879. doi:10.1136/thorax.57.10.875.; GINA Difficult-to-treat and severe asthma in adolescent and adult patient. Global Initiative for Asthma; 2019. Available from: https://ginasthma.org.; Dougherty RH, Sidhu SS, Raman K, et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in TH2-high asthma. J Allergy Clin Immunol. 2010;125(5):1046-1053.e8. doi:10.1016/j.jaci.2010.03.003.; Izuhara K, Conway SJ, Moore BB, et al. Roles of periostin in respiratory disorders. Am J Respir Crit Care Med. 2016;193(9): 949-956. doi:10.1164/rccm.201510-2032PP.; Lopez-Guisa JM, Powers C, File D, et al. Airway epithelial cells from asthmatic children differentially express proremodeling factors. J Allergy Clin Immunol. 2012;129(4):990-997. e996. doi:10.1016/j.jaci.2011.11.035.; Peters MC, Mekonnen ZK, Yuan S, et al. Measures of gene expression in sputum cells can identify T2-high and T2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(4):388-394. doi:10.1016/j.jaci.2013.07.036.; Johansson MW, Annis DS, Mosher DF. aMb2 integrin-mediated adhesion and motility of IL-5 stimulated eosinophils on periostin. 2013;48(4):503-510. doi:10.1165/rcmb.2012-0150OC.; Blanchard C, Mingler MK, McBride M, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol. 2008;1(4):289-296. doi:10.1038/mi.2008.15.; Jia G, Erickson RW, Choy DF, et al. Bronchoscopic exploratory research study of Biomarkers in Corticosteroid-Refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647-654.e10. doi:10.1016/j.jaci.2012.06.025.; Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115-120. doi:10.1136/thoraxjnl-2014-205634.; O'Dwyer DN, Moore BB. Role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci. 2017;74(23):4305-4314. doi:10.1007/s00018-017-2649-z.; Kudo A. Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. Cell Mol Life Sci. 2011;68(19):3201-3207. doi:10.1007/s00018-011-0784-5.; Gillan L, Matei D, Fishman DA, et al. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha (V) beta (3) and alpha (V) beta (5) integrins and promotes cell motility. Cancer Res. 2002;62(18):5358-5364.; Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci. 2009;66(14):2219-2230. doi:10.1007/s00018-009-0013-7.; Kanemitsu Y, Ito I, Niimi A, et al. Osteopontin and periostin associate with a 20-year decline of pulmonary function in asthmatics. Am J Respir Crit Care Med. 2014;190(4):472-474. doi:10.1164/rccm.201403-0562LE.; Hoshino M, Ohtawa J, Akitsu K. Association of airway wall thickness with serum periostinum in steroid-naive asthma. Allergy Asthma Proc. 2016;37(3):225-230. doi:10.2500/aap.2016.37.3945.; Izuhara K, Arima K, Ohta S, et al. Periostin in allergic inflammation. Allergol Int. 2014;63(2):143-151. doi:10.2332/allergolint.13-RAI-0663.; James A, Janson C, Malinovschi A, et al. Serum periostin relates to type-2 inflammation and lung function in asthma: data from the large population-based cohort Swedish GA(2)LEN. Allergy. 2017;72(11):1753-1760. doi:10.1111/all.13181.; Kanemitsu Y, Matsumoto H, Izuhara K, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol. 2013;132(2): 305-312. doi:10.1016/j.jaci.2013.04.050.; Matsusaka M, Kabata H, Fukunaga K, et al. Phenotype of asthma related with high serum periostin levels. Allergol Int. 2015;64(2):175-180. doi:10.1016/j.alit.2014.07.003.; Solanki B, Prakash A, Rehan HS, Gupta LK. Effect of inhaled corticosteroids on serum periostin levels in adult patients with mild-moderate asthma. Allergy Asthma Proc. 2019;40(1):32-34. doi:10.2500/aap.2019.40.4179.; Song JS, You JS, Jeong SI, et al. Serum periostin levels correlate with airway hyper-responsiveness to methacholine and mannitol in children with asthma. Allergy. 2015;70(6):674-681. doi:10.1111/all.12599.; Inoue T, Akashi K, Watanabe M, et al. Periostin as a biomarker for the diagnosis of pediatric asthma. Pediatr Allergy Immunol. 2016;27(5):521-526. doi:10.1111/pai.12575.12.; Cho JH, Kim K, Yoon JW, et al. Serum levels of periostin and exercise-induced bronchoconstriction in asthmatic children. World Allergy Organ J. 2019;(12):1-7. doi:10.1016/j.waojou.2018.11.004.; El Basha NR, Osman HM, Abdelaal AA, et al. Increased expression of serum periostin and YKL40 in children with severe asthma and asthma exacerbation. J Investig Med. 2018;66(8):1102-1108. doi:10.1136/jim-2017-000680.; Масальский С.С., Калмыкова А.С., Уханова О.П. Комплексная оценка сывороточного периостина — нового маркера аллергического воспаления при неконтролируемой бронхиальной астме у детей // Российский аллергологический журнал. — 2018. — Т. 15. — № S1-2. — С. 55-57.; Шахова Н.В., Камалтынова Е.М., Кашинская Т.С. Диагностика бронхиальной астмы у детей в возрасте 3-6 лет с применением сывороточного периостина и суррогатных маркеров эозинофильного воспаления (эозинофилы крови и уровень общего IgE): одномоментное исследование // Вопросы современной педиатрии. — 2019. — Т. 18. — № 2. — С. 118-124. doi:10.15690/vsp.v18i2.2014.; Simpson JL, Yang IA, Upham JW, et al. Periostin levels and eosinophilic inflammation in poorly-controlled asthma. BMC Pulm Med. 2016;16(1):67. doi:10.1186/s12890-016-0230-4.; Takahashi K, Meguro K, Kawashima H, et al. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma. 2019;56(3): 236-243. doi:10.1080/02770903.2018.1455855.; Bobolea I, Barranco P, Del Pozo V, et al. Sputum periostin in patients with different severe asthma phenotypes. Allergy. 2015;70(5):540-546. doi:10.1111/all.12580.; Johansson MW, Evans MD, Crisafi GM, et al. Serum periostin is associated with type 2 immunity in severe asthma. J Allergy Clin Immunol. 2016;137(6):1904-1907.e2. doi:10.1016/j.jaci.2015.12.1346.; Pavlidis S, Takahashi K, Ng Kee Kwong F, et al. T2-high in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur Respir J. 2019;53(1). pii: 1800938. doi:10.1183/13993003.00938-2018.; Habernau Mena A, Del Pozo Abejon V, Rodriguez Vidigal FF, Bobadilla Gonzalez P. Role of periostin in uncontrolled asthma in children (DADO study). J Investig Allergol Clin Immunol. 2017;27(5):291-298. doi:10.18176/jiaci.0144.; Licari A, Brambilla I, Sacchi L, et al. Periostin, type 2 biomarker, is not associated with asthma control grade in asthmatic allergic children. Respir Med. 2019;151:118-120. doi:10.1016/j.rmed.2019.04.010.; Масальский С.С. Диагностическая значимость уровней сывороточного периостина и витамина D при бронхиальной астме у детей школьного возраста: Автореф. дис. . канд. мед. наук. — Ставрополь, 2018. — 23 с. Доступно по: https://search.rsl.ru/ru/record/01008719030. Ссылка активна на 15.04.2019.; Wardzynska A, Makowska JS, Pawelczyk M, et al. Periostin in exhaled breath condensate and in serum of asthmatic patients: relationship to upper and lower airway disease. Allergy Asthma Immunol Res. 2017;9(2):126-132. doi:10.4168/aair.2017.9.2.126.; Lee Y, Lee JH, Yang EM, et al. Serum levels of eosinophilderived neurotoxin: a biomarker for asthma severity in adult asthmatics. Allergy Asthma Immunol Res. 2019;11(3):394-405. doi:10.4168/aair.2019.11.3.394.; Yasuda M, Harada N, Harada S, et al. Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E. Allergy Asthma Clin Immunol. 2018;14:72. doi:10.1186/s13223-018-0300-7.; Carpagnano GE, Scioscia G, Lacedonia D, et al. Looking for airways periostin in severe asthma: could be useful for clustering type 2 endotype? Chest. 2018;154(5):1083-1090. doi:10.1016/j.chest.2018.08.1032.; Масальский С.С., Калмыкова А.С., Уханова О.П., и др. Использование сывороточного периостина в качестве маркера обострений астмы у детей // Аллергология и иммунология в педиатрии. — 2018. — № 4. — С. 37-48.; Scichilone N, Crimi C, Benfante A, et al. Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics. Asthma Res Pract. 2016;2:1. doi 10.1186/s40733-015-0019-x.; Bentley JK, Chen Q, Hong JY, et al. Periostin is required for maximal airways inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol. 2014;134(6):1433-1442. doi:10.1016/j.jaci.2014.05.029.; Patelis A, Alving K, Middelveld R, et al. IgE sensitization to food allergen and airborn allergens in relation to biomarkers of type 2 inflammation in asthma. Clin Exp Allergy. 2018;48(9):1147-1154. doi:10.1111/cea.13165.; Kanemitsu Y, Matsumoto H, Izuhara K, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol. 2013;132(2): 305-312. doi:10.1016/j.jaci.2013.04.050; Mansur AH, Srivastava S, Sahal A. Disconnect of type 2 biomarkers in severe asthma' dominated by FeNo as a predictor of exacerbations and periostin as predictor of reduced lung function. Respir Med. 2018;143:31-38. doi:10.1016/j.rmed.2018.08.005.; Fingleton J, Braithwaite I, Travers J, et al.; NZRHS Study Group. Serum periostin in obstructive airways disease. Eur Respir J. 2016;47(5):1383-1391. doi:10.1183/13993003.01384-2015.
-
6Academic Journal
Συγγραφείς: Ященко, Д. С., Воронович, С. А.
Θεματικοί όροι: хроническая обструктивная болезнь легких, эозинофильное воспаление дыхательных путей
Relation: Ященко, Д. С. Частота встречаемости эозинофильного воспаления дыхательных путей пациентов с обострением хронической обструктивной болезни легких [Электронный ресурс] / Д. С. Ященко, С. А. Воронович // Проблемы и перспективы развития современной медицины : сб. науч. ст. XIV Респ. науч.-практ. конф. с междунар. участием студентов и молодых ученых, Гомель, 5–6 мая 2022 г. : в 6 т. / Гомел. гос. мед. ун-т; редкол. : И. О. Стома [и др. ]. – Гомель : ГомГМУ, 2022. – Т. 1. – C. 283–286. – 1 электрон. опт. диск (CD-ROM). Научный руководитель: ассистент кафедры Н. В. Халецкая; http://elib.gsmu.by/handle/GomSMU/11586
Διαθεσιμότητα: http://elib.gsmu.by/handle/GomSMU/11586
-
7Academic Journal
Συγγραφείς: Димов, И.
Θεματικοί όροι: MYOSITIS EOSINOPHILICA,ЭОЗИНОФИЛЬНОЕ ВОСПАЛЕНИЕ МЫШЦ
Περιγραφή αρχείου: text/html
-
8Academic Journal
Συγγραφείς: Шумилов, П., Дубровская, М., Юдина, О., Мухина, Ю., Тертычный, А.
Θεματικοί όροι: ЭОЗИНОФИЛЬНОЕ ВОСПАЛЕНИЕ, ЭЗОФАГИТ, ГАСТРОЭНТЕРИТ, КОЛИТ, ПИЩЕВАЯ АЛЛЕРГИЯ
Περιγραφή αρχείου: text/html
-
9Academic Journal
Πηγή: VetPharma.
Θεματικοί όροι: ЭОЗИНОФИЛЬНОЕ ВОСПАЛЕНИЕ МЫШЦ
Περιγραφή αρχείου: text/html
-
10Academic Journal
Πηγή: Вопросы современной педиатрии.
Θεματικοί όροι: ЭОЗИНОФИЛЬНОЕ ВОСПАЛЕНИЕ, ЭЗОФАГИТ, ГАСТРОЭНТЕРИТ, КОЛИТ, ПИЩЕВАЯ АЛЛЕРГИЯ, 3. Good health
Περιγραφή αρχείου: text/html
-
11
